Skip to main content

The long and winding road: perspectives of people and parents of children with mitochondrial conditions negotiating management after diagnosis

Abstract

Background

The diagnostic odyssey for people with a rare disease is well known, but difficulties do not stop at diagnosis. Here we investigate the experience of people, or parents of children with a diagnosed mitochondrial respiratory chain disorder (MRCD) in the management of their disease. The work complements ongoing projects around implementation of consensus recommendations for management of people with MRCD. People with or caring for a child with a formally diagnosed MRCD were invited to take part in an hour-long focus group held via videoconference. Questions elicited experiences of receiving management advice or information specific to their MRCD in four areas drawn from the consensus recommendations: diet and supplements, exercise, access to social services, and mental health. Sessions were audio-recorded, transcribed and analysed using a combination of inductive and deductive coding.

Results

Focus groups were conducted with 20 participants from five Australian states in June–September 2020. Fourteen adults with a MRCD (three of whom also had a child with a MRCD), and six who cared for a child with a MRCD took part. The overarching finding was that of the need for ongoing negotiation to access the advice and service required to manage their condition. The nature of these negotiations varied across contexts but mostly related to joint decision-making, and more commonly, the need to advocate for their care with non-specialist services (e.g., dieticians, schools). The effort required for this self-advocacy was a prominent theme. While most participants reported receiving adequate advice around supplements, and to a lesser extent diet and exercise, the majority reported no formal advice around mental health or practical assistance accessing social services.

Conclusion

These focus groups have revealed several gaps in the system for people with a MRCD, interacting with care providers after diagnosis. Focus group participants had to negotiate with a range of different stakeholders in order to secure appropriate advice or services. Notable was the gap in appropriate generalist services (e.g., dieticians) with sufficient knowledge of MRCD to support people with their day-to-day challenges.

Introduction

The long and winding road that leads to your door

Will never disappear; I’ve seen that road before.

[Lennon and McCartney, Apple Music]

Mitochondrial Respiratory Chain Disorders (MRCDs) are among the most common inborn errors of metabolism, with a conservative estimated incidence for severe MRCD of 1 in 5,000 births [1]. Most of these disorders present during infancy, with a median survival rate of 12 years [2]. Childhood presentations tend to have a more severe and acute phenotype [3], while adult cases often have milder chronic phenotypes [4]. MRCDs can affect any organ, with highly variable clinical presentations, usually involving multiple systems [3, 5, 6].

A major research project is currently underway in Australia to develop a rapid genetic diagnostic process for mitochondrial conditions using next generation sequencing technologies (Australian Genomics Health Alliance Mitochondrial Flagship) [7, 8]. However, an issue that remains is how best to manage patients once a diagnosis has been established.

This challenge is commonly encountered by others with a rare disease. In a systematic review of people’s psychosocial experiences of rare disease [9], 14 of the 21 articles found that meeting health professionals with poor knowledge of their rare diagnosis was common and could result in lack of actionable information, distrust, inappropriate treatments [10, 11], and difficulty in accessing social services [12]. Survey results from 547 people with a rare condition and 214 carers highlighted the importance of support from online and face-to-face peer or charity support groups to alleviate this lack of knowledge [13]. Mental health issues for people with a rare condition is also common, with many patients and carers reporting they had never been asked about their mental health [13, 14].

There are currently very few effective therapies for MRCDs, but there is a level of consensus [15], and some evidence, for treatments that can alleviate symptoms and improve quality of life. Benefits have been associated with interventions around nutrition, supplements and cofactor therapy [16], exercise [17], and active screening for mental health issues [18].

MRCDs are diverse and the initial health issues that patients face are variable, usually differing in paediatric and adult-onset forms of the disorder. Clinical features evolve over time, further complicating approaches to management. It is therefore not surprising that the approaches to management can vary considerably from one clinical centre to another. To address this variability, and the possible sub-optimal care that may result, an international consortium of experts developed recommendations for the management of patients with MRCDs based on best available evidence and consensus of experts [15].

This current study aimed to understand the experience of MRCD management in the Australian context from the perspective of people living with a diagnosed MRCD, or parents of children with a diagnosed MRCD.

Results

Focus groups were conducted with 20 participants resident in five states of Australia (New South Wales, Victoria, Queensland, South Australia, Western Australia) in June–September 2020. There were 14 participants who had a MRCD and nine participants who cared for a child with a MRCD. Three people with MRCD themselves also cared for a child or children with a MRCD. Two parents had cared for children that had died. Table 1(a) has participant details. Only one enrolled participant did not attend. Surveys were completed by most of the focus group participants; 20 completed the pre-group survey and 13 the post group survey. Table 1(b, c) shows results.

Table 1 Details of (a) focus group participants, N = 23, (b) pre-focus group survey responses N = 20 and (c) post-focus group survey responses N = 13

Negotiation of care

The most striking theme to emerge from the focus groups was the ongoing need to negotiate for every aspect of care. In contrast to service provision encounters for people with high prevalence conditions, consultations regarding MRCDs involved a negotiation and sometimes a ‘testing’ between the stakeholders. Negotiation was seen to occur across different settings and between different pairs of the identified stakeholder groups as well: between the patient or parent and the MRCD specialist services, generalist health services, social services, schools, family and friends and informal support services. The nature of these negotiations varied across contexts. For example, with specialist services, negotiations were predominantly around management decisions where there was uncertainty due to a lack of clear evidence. Negotiations with other non-specialist health and social care providers were around advocating for appropriate care. Similar issues arose for both adults and parents. Example quotes are given in Table 2 around these negotiations.

Table 2 Example quotes showing negotiation between person/parent of a child with a MRCD and other stakeholder groups

A range of documents were mentioned by participants as facilitating negotiations. A letter stating the diagnosis was seen as very useful, as were information booklets from the Mito Foundation (e.g., for schools or GPs). Some participants had personal copies of their comprehensive plans of care yet noted that they were rarely looked at by other health providers. Requests, either written or verbal for new health providers to call the MRCD specialist team before initiating any treatment was reported as often ignored.

Effort of self-advocacy

Considerable effort was reported by participants around negotiating and advocating for their own or their child’s care:

You have to do so much ringing around to find [a physio] that’s even got an inkling of an understanding of what the problem is. [AdultFG0307P8]

I would say it took me a good 12 months to even manage to lodge all the paperwork and report everything required for the [NDIS] plan [for my child with MRCD] and the process itself was incredibly distressing, and I was just lucky that I came across someone who helped me actually navigate that process because it was extremely difficult to lodge the paperwork given how much time we spend in medical and therapy appointments. [ParentFG0109P13]

Positive interactions

Figure 1 shows a graphical representation of the matrix of all reported positive negotiations regarding management of MRCD. Arrows indicate the direction of the negotiation; i.e., if a patient initiates a negotiation of care with a MRCD specialist, the arrow is shown as going from the patient, pointing to the MRCD specialist. Double ended arrows indicate two-way negotiation. An example of a negotiation between MRCD specialist service and general health provider:

My specialist did write to my personal trainer and said that exercise was important and that I would probably need a sugary snack before I did any exercise. [AdultFG0109P13]

Fig. 1
figure1

Reported links between different stakeholders in the negotiation of care for a MRCD. Size of the node (each of which represent a different stakeholder group) indicates the frequency of reported links (i.e., larger nodes are involved in more links)

Missed opportunities to negotiate

Figure 2 shows a graphical representation of the matrix of all reported negative or missed opportunities to negotiate regarding management of the MRCD. Most missed opportunities were reported between adults or parents of children with MRCD and specialist or generalist health services. However, missed opportunities to access social care had the most negative impact.

I personally drilled my GP to make sure everything we do she uploads onto the master database that doctors and everybody can access. She does her bit, but then I go to the next specialist, or the next mito meeting and they ask me the questions which have already been answered had they taken the time to read this stuff. [AdultFG0307P8]

No, same thing [as the other participants] ... like you ask [about accessing social care] ... but unless you know someone or something then... no... you have to dig really hard to find anything. [AdultFG3006P3]

NDIS only provides… when I said [child 1] had mito, it was “okay well she can have this much” and it was very small. But when I mentioned that [child 2] has autism they said “how much do you want?” I feel like I can manage [the child with autism] but not manage [the child with MRCD]. [ParentsFG0109P14]

We got offered a social worker who added zero value unfortunately, and I just opted out of that. [ParentFG2306P2]

The journey through the NDIS [National Disability Insurance Scheme] was horrific for us. It was terrible. We were never heard. I had to time and time again prove why my child needed to be eligible [ParentFG0307P6]

Fig. 2
figure2

Reported missed links between different stakeholders in the negotiation of care for a MRCD. Size of the node (each of which represent a different stakeholder group) indicates the frequency of the missed opportunities to link (i.e., larger nodes are involved in more missed links). Arrows point to the stakeholder experiencing the negative effect of the missed opportunity

Cross-cutting themes

A number of themes were identified that were associated in different ways with negotiations with the five stakeholder groups. Table 3 shows the cross-cutting themes by stakeholder negotiation with exemplar quotes to illustrate each.

Table 3 Exemplar quotes from the focus groups showing cross-cutting themes within the overarching concept of negotiation of care

Impact of cost

Many participants talked about out-of-pocket costs arising from positive or negative negotiations with health and social care providers around the management of their MRCD. Costs associated with purchasing recommended supplements, paying for allied health services, and lost earnings were commonly reported.

Uncertainty

The uncertainty of management options and prognosis was commonly reported. While this understandably often related to generalist health providers who may not have seen a person with a MRCD before, it also included interactions with the more knowledgeable MRCD specialist teams. As well as lack of clinical experience, uncertainty was also linked to a lack of evidence to assist with decision-making.

Trial and error

Trial and error was commonly reported as an approach to management when evidence was lacking. While some participants accepted this as part and parcel of a rare diagnosis, it caused others considerable distress.

Trust

There was a mixture of positive and negative sentiments expressed in the theme of trust. Some participants expressed gratitude and confidence in MRCD specialists or generalist health providers with whom they had a good rapport. The Mito Foundation was mentioned in several focus groups as providing trustworthy, high quality information and support. Lack of trust arose from service providers (e.g., specialists not experienced in MRCD) who did not listen to concerns (including failing to accept their diagnosis), or erroneously thought they knew more than they did. Other health providers admitted to being out of their depth and so withdrew their service, breaching the participants’ trust and leaving them without support.

Transition from paediatric to adult services

As with many other long-term conditions, the transition from paediatric to adult services was generally seen as a negative experience. Parents reported that transitions for their children meant a loss of a ‘holistic’ approach and certain services, only accessible to paediatric patients, were no longer available, e.g., specialist dietician.

Comments on individual topic areas

Four topic areas (exercise, nutrition and supplements, social care, and mental wellbeing) were used as a framework to guide the discussions of management experiences. Most participants had been advised on the use and (for some) the lack of clear evidence around various supplements. Most participants were familiar with the idea of a “mito cocktail” (a mix of supplements and vitamins with limited high-quality evidence but believed by some to be helpful). Issues around accessing social services were spoken of with the most frustration and passion, with onerous application processes and strong bias of approval for services towards high incidence conditions. Mental health advice had not been given for the majority of participants, often due to it being overshadowed by more pressing physical issues. Three people reported having it raised formally as an issue. Only one of these was given access to a psychologist for their child “from the outset” which they described as “a good experience” [ParentFG2306P1]. Others reported seeking help for themselves or had GPs who facilitated access to counselling.

Discussion

We held focus groups with twenty people either living with a MRCD, caring for a child with MRCD, or both, exploring their experience of managing their disease after a genetic diagnosis is achieved. The data revealed an overarching concept of an ongoing negotiation of care across contexts: with specialist MRCD services, generalist health services, social service providers, family and friends, and informal support services. Five cross-cutting themes were also found: impact of out-of-pocket costs, trust, uncertainty, trial and error, and transition from paediatric to adult services. Management advice on the four topics was generally good for supplements and diet, slightly less helpful for physical activity, often poor for accessing social care, and virtually non-existent regarding mental health.

The concept of having to negotiate and advocate for one’s care after diagnosis of a rare disease has been reported previously, but studies of this kind are rare. Budych and colleagues noted that there is a well-established information asymmetry between the physician, holding knowledge and skills about the condition, and the patient with a high incidence condition who plays a more passive role [19]. Rare diseases and their accompanying lack of clear evidence around treatment and management options disrupt this dynamic. This can put the patient in the position of having to advocate for their care and become knowledgeable about the condition themselves. The success of this approach is predicated by the physician or other care provider accepting that the patient holds expertise they do not.

Equipping the patient as an expert of their own condition is a key tenet of action and the basis of policies to improve outcomes for people with rare diseases. For example, the European Organisation for Rare Diseases (EURORDIS) states patient empowerment as a key aim: “building the capacities of patients we empower them to become advocates equipped with the knowledge and skills needed to fight for better lives” [20]. Participants in our focus group showed themselves to be very knowledgeable about many aspects of their, or their child’s, condition. Some participants reported respectful and acceptable negotiations using a trial and error approach, in the context of an informed and up-to-date health provider but uncertain evidence. Others reported a failure of health or social care providers to negotiate or even to engage.

Negotiations with the social care provider, the National Disability Insurance Scheme, were mentioned by many participants, mostly expressing frustration. This publicly funded scheme was initiated in 2014 with a staggered implementation across Australia. Its aim is to provide flexible social support packages for people with disabilities [21]. Although considerable efforts considerable efforts have been made by the agency to streamline and simplify the application process, issues persist (e.g., [22]) largely due to algorithms based on “typical” needs of standardised, high incidence conditions [23]. Lack of knowledge about the complex needs of people with a rare disease was reported by our participants as a significant barrier to accessing appropriate levels of social care.

Missed opportunities to interact were reported and were often due to lack of timely or appropriate communication. Lack of communication between different health care providers, even within the same organisation has been reported in other studies (e.g., in the NHS [24]) and is not restricted to communication around people with a rare disease (e.g., people with an acute mental health issue [25]). A patient seeing a health care provider working on their own may be confident of receiving high quality care if their provider follows easily accessible and widely accepted evidence-based guidelines. However, in the context of a rare disease, with little guidance and a management plan that may have to be worked out through trial and error, it is difficult to justify working in isolation. Poorer outcomes can be expected as a result of duplication of assessments or trials and the accompanying waste of time and resources, and decreased patient satisfaction and trust.

In the context of the larger research program that is looking at the active implementation of management guidelines, a clear message from the focus groups was that many of the key management areas affecting the lives of people with a MRCD were not being addressed adequately. Outside of the rare disease context, advice on diet, exercise or mental health is usually referred to appropriate general or allied health practitioners. Here, there was a reported gap and participants spoke about the struggle to find appropriately knowledgeable GPs, exercise physiologists, and dieticians. The gap was often filled by advocacy agency websites such as the Mito Foundation, international Facebook groups and other websites. Advice around accessing social care was mixed. While there were some positive reports of a few MRCD specialist providers who actively facilitated application for NDIS services, a number of participants felt it was left completely to them.

We began with a quote from John Lennon and Paul McCartney’s famous song. That never-ending journey brings to mind both the all-too-common diagnostic odyssey, and also the ongoing journey described here that patients, parents and their children must undergo in the search for continuing care for their condition.

Limitations

The use of online focus groups may have limited participation by those less digitally confident or equipped. However, it had the advantage of more easily engaging participants from rural and remote areas. There is also the possibility that the topic of the focus groups skewed representation to more proactive and informed people. Recruitment was via the Mito Foundation, so positive comments about that agency’s support should be viewed in that light.

A strength of the study was participants all had a formal diagnosis of MRCD rather than people suspected of MRCD who may still be on the diagnostic odyssey. Questions could therefore concentrate on management across their care journey rather than diagnosis.

Conclusion

People with a rare disease face many challenges when interacting with care providers after diagnosis. Focus group participants reported having to negotiate with these providers in order to get appropriate advice on management. Success in negotiation was predicated by the health or care provider accepting that there is a different dynamic between them and working alongside them. Most positive interactions were reported with individual MRCD specialist services, individual generalist providers who were seen as going above and beyond, and support groups such as the Mito Foundation. Advice on diet and exercise were most commonly given although follow up with appropriate generalist services (e.g., dietician) was difficult due to lack of knowledge about MRCD disease. Services or providers that facilitated access to social care were greatly appreciated and stood in contrast to the frustration and confusion of those left to work it out themselves. Consistent with other studies in the rare disease field, few participants reported having their mental health formally addressed or assessed at any time.

The strong push from rare disease groups internationally to empower patients to advocate for their own care can only be successful where health providers accept the expertise of the person with a rare disease and agree to work together. Here we see that this is not always the case and the odyssey may continue.

Methods

This was a mixed methods exploratory study using two short surveys and two parallel sets of focus groups. Ethical approval was given by Royal Children’s Hospital Human Research Ethics Committee (61859/RCHM-2020).

Focus groups

The consumer advocacy agency, The Mito Foundation facilitated recruitment from across Australia by calling for expressions of interest to take part in a 60-min virtual focus group. Participants were recruited separately for each of the two categories of focus groups: (1) people with a genetically diagnosed MRCD, and (2) parents/carers of children with a genetically diagnosed MRCD. Some participants fit both criteria. We specified “genetically diagnosed” to ensure we recruited people who had interacted with a specialist service and were being managed as a person with a MRCD (rather than suspicion of a MRCD).

A participant information sheet provided general information about the project and the aim. It explained how the group would be run, encouraged respect for the views of the other participants, and stated that comments made in the group would be all de-identified. A brief, plain English summary of the consensus recommendations was provided to give some context, and to frame the questions we asked. We asked participants about advice they had received from health professionals about aspects of their management of their (or their child’s) MRCD, chosen for their applicability to all people with a MRCD. The four areas, taken from the consensus guidelines [15] were: (a) nutrition and supplements, (b) exercise, (c) access to social care, and (d) mental health. We asked who gave them the advice, and the nature of that advice. Participants who fitted the criteria for having a MRCD themselves but also had a child with a MRCD, were asked to consider the questions from the two viewpoints separately. The full schedule of questions is provided in Additional file 1: File #1.

Six to eight participants were recruited into each focus group to give us an optimal number of attendees for the online medium [26]. Participation was voluntary and participants could withdraw at any time without having to give a reason.

As recruitment occurred during the COVID-19 pandemic, all focus groups were held over the video conferencing application, Zoom [27]. Participants joined via a secure link. The focus groups were run by two experienced qualitative researchers (SB, JL) with clinical backgrounds, and the sessions were audio-recorded. The Mito Foundation ensured that a Mito Foundation Helpline resource was available to participants after each focus group for telephone assistance or debriefing if needed.

Surveys

Participants were emailed an anonymous link to an online survey before the focus group and another after. Each survey took around 10 min to complete and was not a prerequisite for participation in the focus group. The pre-focus group survey collected general demographic data about the participants such as length of time they had been engaging with the health system for their/their child’s MRCD, length of time since diagnosis, which health professional cared for them at the time of diagnosis, and information about their current MRCD specialist care team. The post-focus group survey asked about their impression of the brief summary of the consensus recommendations (see Additional file 2: File #2); specifically, did they make sense, and were they useful?

Analysis

Data from the focus groups was transcribed verbatim by the research team, imported into QSR International Pty Ltd. Nvivo Qualitatitve Data Analysis and Software Version 12. 2018 for analysis and identifiable features of the experiences, or personal details shared in the group were changed. Transcripts were read for familiarisation and discussed in the coding team (SB, SH, TT and JL) who worked collaboratively over a series of meetings to compile a list of high-level concepts inductively. To aid the analysis, five stakeholder groups who interacted with the focal person with a MRCD were defined: (1) MRCD specialist health providers, (2) non-MRCD specialist health providers (e.g., general practitioners (GPs), physiotherapists, cardiologists), (3) social care providers (e.g., the National Disability Support Service, Home Care), (4) family and friends, and (5) informal support groups (e.g., the Mito Foundation, Facebook groups).

Each of the research team members independently coded a transcript and then discussed findings in the team and considered additional themes. Further discussion led to the identification of an overarching concept of ‘negotiation of care’ enacted within various contexts (e.g., between patient and MRCD specialist team; between MRCD specialist and social care provider), with a set of other themes that were components of these negotiations. Transcripts were then coded deductively (by SH and TT) using this framework. Results were compared and discussed by the coding team as coding proceeded and further insights drawn out. The frequency of negotiations between patients, MRCD services, non-MRCD services, informal support groups, family and friends, and social services were put into a matrix. Frequency of missed opportunities to negotiate were also compiled. These two matrices were converted to graphics using social network software, UCINet [28]. Survey results were analysed using descriptive statistics. Free text answers were used to provide context.

Availability of data and materials

Raw data is not available as per Ethical requirements to keep focus group data not identifiable. Focus group schedule, and de-identified quotes are supplied.

Abbreviations

GP:

General practitioner (family physician)

MRCD:

Mitochondrial respiratory chain disorder

NDIS:

National Disability Support Service

References

  1. 1.

    Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis. 2004;27(3):349–62.

    CAS  Article  Google Scholar 

  2. 2.

    Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49(3):377–83.

    CAS  Article  Google Scholar 

  3. 3.

    Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. J Neurol Neurosurg Psychiatry. 2009;80(9):943–53.

    CAS  Article  Google Scholar 

  4. 4.

    Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med (Helsinki). 2013;45(1):4–16.

    CAS  Article  Google Scholar 

  5. 5.

    Davis RL, Sue CM. The genetics of mitochondrial disease. Semin Neurol. 2011;31(5):519–30.

    Article  Google Scholar 

  6. 6.

    DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348(26):2656–68.

    CAS  Article  Google Scholar 

  7. 7.

    Akesson LS, Eggers S, Love CJ, Chong B, Krzesinski EI, Brown NJ, et al. Early diagnosis of Pearson syndrome in neonatal intensive care following rapid mitochondrial genome sequencing in tandem with exome sequencing. Eur J Hum Genet. 2019;27(12):1821–6.

    CAS  Article  Google Scholar 

  8. 8.

    Stark Z, Boughtwood T, Phillips P, Christodoulou J, Hansen DP, Braithwaite J, et al. Australian genomics: a federated model for integrating genomics into healthcare. Am J Hum Genetics. 2019;105(1):7–14.

    CAS  Article  Google Scholar 

  9. 9.

    von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: A systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5(6):758–73.

    Article  Google Scholar 

  10. 10.

    Barlow JH, Stapley J, Ellard DR. Living with haemophilia and von Willebrand’s: a descriptive qualitative study. Patient Educ Couns. 2007;68(3):235–42.

    Article  Google Scholar 

  11. 11.

    Dures E, Morris M, Gleeson K, Rumsey N. The psychosocial impact of Epidermolysis Bullosa. Qual Health Res. 2011;21(6):771–82.

    Article  Google Scholar 

  12. 12.

    Grut L, Kvam M-H. Facing ignorance: people with rare disorders and their experiences with public health and welfare services. Scand J Disabil Res SJDR. 2013;15(1):20–32.

    Article  Google Scholar 

  13. 13.

    Rare Diseases UK. Living with a rare condition: the effect on mental health. 2018; Accessed 18 August, 2020. Available from: https://www.raredisease.org.uk/wp-content/uploads/sites/7/2018/07/living-with-a-rare-condition-the-effect-on-mental-health-pdf.pdf

  14. 14.

    Koerling A-L. No friends 1. Orphanet J Rare Dis. 2020;15(1):50.

    Article  Google Scholar 

  15. 15.

    Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017;19(12):1380.

    Google Scholar 

  16. 16.

    El-Hattab AW, Hsu JW, Emrick LT, Wong LJC, Craigen WJ, Jahoor F, et al. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet Metab. 2012;105(4):607–14.

    CAS  Article  Google Scholar 

  17. 17.

    Bates MGD, Newman JH, Jakovljevic DG, Hollingsworth KG, Alston CL, Zalewski P, et al. Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease. Int J Cardiol. 2013;168(4):3599–608.

    Article  Google Scholar 

  18. 18.

    Mancuso M, Mancuso M, Orsucci D, Orsucci D, Ienco EC, Ienco EC, et al. Psychiatric involvement in adult patients with mitochondrial disease. Neurol Sci. 2013;34(1):71–4.

    Article  Google Scholar 

  19. 19.

    Budych K, Helms TM, Schultz C. How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient–physician interaction. Health Policy. 2012;105(2):154–64.

    Article  Google Scholar 

  20. 20.

    Le Cam Y, Bolz-Johnson M. Expert by experience: valuing patient engagement in healthcare. In: Pomey M-P, Denis J-L, Dumez V, editors. Patient engagement: how patient-provider partnerships transform healthcare organisations. Cham: Palgrave Macmillan; 2019. p. 233–67.

    Chapter  Google Scholar 

  21. 21.

    National Disability Insurance Agency. National Disability Insurance Scheme 2021. Available from: https://www.ndis.gov.au/.

  22. 22.

    Barr M, Duncan J, Dally K. Parent experience of the national disability insurance scheme (NDIS) for children with hearing loss in Australia. Disabil Soc. 2020:1–25.

  23. 23.

    King M. Dedifferentiation and difference: people with profound intellectual and multiple disabilities and the National Disability Insurance Scheme (NDIS). J Intellect Dev Disabil. 2020;45(4):320–5.

    Article  Google Scholar 

  24. 24.

    Crowe AL, McKnight AJ, McAneney H. Communication needs for individuals with rare diseases within and around the healthcare system of northern Ireland. Front Public Health. 2019;7:236.

    Article  Google Scholar 

  25. 25.

    Esposito JM, Fein JA, Marshall J, Mitchell C, Aredas B, Zorc JJ. Improving mental health communication from the pediatric emergency department to primary care. 2020;36(9):424–9.

  26. 26.

    Jacqueline MB. Review: Michael Bloor, Jane Frankland, Michelle Thomas, Kate Robson. Focus groups in social research. Forum Qual Soc Res. 2002;3(4).

  27. 27.

    Zoom Video Communications Inc. Zoom 2016. Available from: https://zoom.us/.

  28. 28.

    Borgatti SP, Everett MG, Freeman LC. UCInet for windows: software for social network analysis. 6 ed. Harvard: Analytic Technologies; 2002.

Download references

Acknowledgements

We thank our participants and The Mito Foundation for providing logistical support.

Funding

This work was funded by a Mito Foundation Project Grant 2019–2021.

Author information

Affiliations

Authors

Contributions

JC, JB, SB and JL conceived the study. JL, SB, TT and SH collected data and performed the analysis. JL drafted the manuscript. JC, JB, TC and SM reviewed and made comments on the manuscript. All authors reviewed the final draft. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Janet C. Long.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was given by Royal Children’s Hospital Human Research Ethics Committee (61859/RCHM-2020). Written consent was given by all participants after reviewing the Participant Information Sheet.

Consent for publication

No personally identifiable data is contained in this article.

Competing interests

Authors SM and TC are staff members of The Mito Foundation. JL, SB, TT, SH and JB declare they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Full schedule of questions used in the focus groups.

Additional file 2.

Brief summary of the consensus recommendations provided to the focus group participants prior to the session.

Additional file 3.

Consolidated criteria for reporting qualitative studies (COREQ) checklist.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Long, J.C., Best, S., Hatem, S. et al. The long and winding road: perspectives of people and parents of children with mitochondrial conditions negotiating management after diagnosis. Orphanet J Rare Dis 16, 310 (2021). https://doi.org/10.1186/s13023-021-01939-6

Download citation

Keywords

  • Qualitative research
  • Rare disease
  • Management
  • Consumer experience
  • Mitochondrial